Drugs / Fumaryl Diketopiperazine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00721344 | Apr → Aug 2008 | — | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00626249 | Aug 2007 → Sep 2008 | diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fumaryl Diketopiperazine | “A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With...” NCT00626249 ↗1“A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine...” NCT00721344 ↗ |
| Known as | FDKP | “Technosphere Inhalation Powder (FDKP)” NCT00721344 ↗ |
| Route | Inhaled | “given at Visit 2 via MedTone® Inhaler” NCT00626249 ↗ |